AbbVie Inc. (ABBV) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
AbbVie Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net earnings → Net cash from operating activities: $3,436,000,000.00Net earnings → Operating adjustments reconciliation: $180,000,000.00Amortization of intangible assets → Operating adjustments reconciliation: $1,689,000,000.00Change in fair value of contingent consideration liabilities → Operating adjustments reconciliation: $1,518,000,000.00Accounts payable and other liabilities → Operating adjustments reconciliation: $1,202,000,000.00Acquired IPR&D and milestones → Operating adjustments reconciliation: $291,000,000.00Depreciation → Operating adjustments reconciliation: $194,000,000.00Stock-based compensation → Operating adjustments reconciliation: $166,000,000.00Other, net → Operating adjustments reconciliation: $4,000,000.00Operating adjustments reconciliation → Income tax assets and liabilities, net: $2,223,000,000.00Operating adjustments reconciliation → Accounts receivable: $1,369,000,000.00Operating adjustments reconciliation → Payments of contingent consideration liabilities: $1,062,000,000.00Operating adjustments reconciliation → Deferred income taxes: $195,000,000.00Operating adjustments reconciliation → Prepaid expenses and other assets: $188,000,000.00Operating adjustments reconciliation → Inventories: $143,000,000.00Operating adjustments reconciliation → Non-cash litigation reserve adjustments, net of cash payments: $64,000,000.00Net cash used in investing activities → investing reconciliation: $1,197,000,000.00investing reconciliation → Other acquisitions and investments, net of cash acquired: $824,000,000.00investing reconciliation → Acquisitions of property and equipment: $322,000,000.00investing reconciliation → Other, net: $51,000,000.00Net cash used in financing activities → financing reconciliation: $5,054,000,000.00Other, net → financing reconciliation: $25,000,000.00financing reconciliation → Dividends paid: $3,070,000,000.00financing reconciliation → Repayments of long-term debt: $2,000,000,000.00financing reconciliation → Purchases of treasury stock: $9,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $9,391,000,000.00Net cash from operating activities → Cash sources and uses: $3,436,000,000.00Cash sources and uses → Exchange-rate effect: $7,000,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $6,569,000,000.00Cash sources and uses → Net cash used in investing activities: $1,197,000,000.00Cash sources and uses → Net cash used in financing activities: $5,054,000,000.00Net earnings: $3,616,000,000.00Net earnings+$3.62 BDepreciation: $194,000,000.00Depreciation expense+$194.00 MAmortization of intangible assets: $1,689,000,000.00Intangible amortization+$1.69 BDeferred income taxes: -$195,000,000.00Deferred income taxes−$195.00 MChange in fair value of contingent consideration liabilities: $1,518,000,000.00Contingent consideration change+$1.52 BPayments of contingent consideration liabilities: -$1,062,000,000.00Contingent consideration paid−$1.06 BStock-based compensation: $166,000,000.00Stock-based compensation+$166.00 MAcquired IPR&D and milestones: $291,000,000.00Acquired IPR&D written off+$291.00 MNon-cash litigation reserve adjustments, net of cash payments: -$64,000,000.00Non-cash litigation, net−$64.00 MOther, net: $4,000,000.00Other non-cash items+$4.00 MAccounts receivable: -$1,369,000,000.00Accounts receivable−$1.37 BInventories: -$143,000,000.00Inventories−$143.00 MPrepaid expenses and other assets: -$188,000,000.00Prepaid & other assets−$188.00 MAccounts payable and other liabilities: $1,202,000,000.00Payables & accrued liabilities+$1.20 BIncome tax assets and liabilities, net: -$2,223,000,000.00Income taxes, net−$2.22 BNet cash from operating activities: $3,436,000,000.00Operating cash+$3.44 BOperating adjustments reconciliation: $5,244,000,000.00Net change in commercial paper borrowings with original maturities of three months or less: $0.00Proceeds from issuance of other short-term borrowings: $0.00Repayments of other short-term borrowings: $0.00Proceeds from issuance of long-term debt: $0.00Repayments of long-term debt: -$2,000,000,000.00Debt & capital securities repaid−$2.00 BDividends paid: -$3,070,000,000.00Dividends paid−$3.07 BPurchases of treasury stock: -$9,000,000.00Common stock repurchases−$9.00 MOther, net: $25,000,000.00Other financing, net+$25.00 MNet cash used in financing activities: -$5,054,000,000.00. Cash required to fund net payments.Financing cash−$5.05 Bfinancing reconciliation: $5,079,000,000.00Acquisitions of businesses, net of cash acquired: $0.00Other acquisitions and investments, net of cash acquired: -$824,000,000.00Other investment purchases−$824.00 MAcquisitions of property and equipment: -$322,000,000.00PP&E purchases−$322.00 MOther, net: -$51,000,000.00Other investing, net−$51.00 MNet cash used in investing activities: -$1,197,000,000.00. Cash required to fund net payments.Investing cash−$1.20 Binvesting reconciliation: $1,197,000,000.00Cash sources and uses: $12,827,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $9,391,000,000.00Beginning cash$9.39 BEnding cash: Cash, cash equivalents, and restricted cash: $6,569,000,000.00Ending cash$6.57 BExchange-rate effect: -$7,000,000.00FX effect−$7.00 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$3.11 BOperating cash − cash spent on PP&ECash flow / Net income0.95×Operating cash flow ÷ net incomeNet cash change−$2.82 BEnding cash − beginning cash
Chart details

AbbVie Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
9,391,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
3,436,000,000 US dollars. Net cash provided.
Net earnings
3,616,000,000 US dollars
Depreciation
194,000,000 US dollars
Amortization of intangible assets
1,689,000,000 US dollars
Deferred income taxes
negative 195,000,000 US dollars
Change in fair value of contingent consideration liabilities
1,518,000,000 US dollars
Payments of contingent consideration liabilities
negative 1,062,000,000 US dollars
Stock-based compensation
166,000,000 US dollars
Acquired IPR&D and milestones
291,000,000 US dollars
Non-cash litigation reserve adjustments, net of cash payments
negative 64,000,000 US dollars
Other, net
4,000,000 US dollars
Accounts receivable
negative 1,369,000,000 US dollars
Inventories
negative 143,000,000 US dollars
Prepaid expenses and other assets
negative 188,000,000 US dollars
Accounts payable and other liabilities
1,202,000,000 US dollars
Income tax assets and liabilities, net
negative 2,223,000,000 US dollars
Investing activities
negative 1,197,000,000 US dollars. Net cash used.
Acquisitions of businesses, net of cash acquired
0 US dollars
Other acquisitions and investments, net of cash acquired
negative 824,000,000 US dollars
Acquisitions of property and equipment
negative 322,000,000 US dollars
Other, net
negative 51,000,000 US dollars
Financing activities
negative 5,054,000,000 US dollars. Net cash used.
Net change in commercial paper borrowings with original maturities of three months or less
0 US dollars
Proceeds from issuance of other short-term borrowings
0 US dollars
Repayments of other short-term borrowings
0 US dollars
Proceeds from issuance of long-term debt
0 US dollars
Repayments of long-term debt
negative 2,000,000,000 US dollars
Dividends paid
negative 3,070,000,000 US dollars
Purchases of treasury stock
negative 9,000,000 US dollars
Other, net
25,000,000 US dollars
Operating adjustment reconciliation
5,244,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
5,079,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
1,197,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 7,000,000 US dollars
Ending cash on Jun 30, 2026
6,569,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
12,827,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 2,822,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.95×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
3,436,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
322,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
3,114,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $3.44B of net income directly to operating cash and $180.00M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 3,436,000,000 US dollars minus 322,000,000 US dollars equals 3,114,000,000 US dollars.
AbbVie Inc. (ABBV) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!